SAB Biotherapeutics gains on manufacturing agreement with Emergent

SAB Biotherapeutics

27/10/2022 17:31

** Shares of drug developer SAB Biotherapeutics  SABS.O 
jump ~13% to 89 cents 
    ** SABS says entered into an exclusive manufacturing
services agreement with Emergent BioSolutions  EBS.N 
 urn:newsml:reuters.com:*:nGNXbVtny4 
    ** EBS to provide contract development and manufacturing
services to produce SABS polyclonal antibody drug candidates and
support SABS' clinical programs
    ** SABS did not disclose the financial details of the deal
    ** Including session moves, SABS down ~89% while EBS down
~51% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))